Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib in Japanese patients with hematologic malignancies or AML
NCT03135028Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- May 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of entospletinib in hematologic malignancy and acute myeloid leukemia (AML) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Dose Limiting Toxicities. Started May 2017; status: terminated.
02
Drugs
entospletinib
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03135028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135028.